| 1357 |
National Cancer Institute |
Html |
en |
Fatigue (PDQ®)–Health Professional Version |
Expert-reviewed information summary about fatigue, a condition marked by extreme tiredness and inability to function because of lack of energy, often seen as a complication of cancer or its treatment. |
| fatigue syndrome | 0.551792 |
| severe fatigue | 0.49185 |
| cancer-related fatigue | 0.710712 |
| Fatigue Coalition | 0.462842 |
| fatigue ratings | 0.435783 |
| fatigue | 0.998693 |
| exhibit peak fatigue | 0.502775 |
| fatigue severity | 0.46154 |
| Cancer Nurs | 0.388926 |
| fatigue outcomes. | 0.43447 |
| evening fatigue | 0.483354 |
| muscle fatigue | 0.440015 |
| chronic fatigue | 0.543247 |
| cancer treatment–related fatigue | 0.605063 |
| breast cancer patients | 0.407613 |
| patients | 0.57543 |
| cancer patients | 0.477381 |
| Fatigue Symptom Inventory | 0.497603 |
| breast cancer survivors | 0.539985 |
| cancer survivors | 0.554969 |
| radiation therapy | 0.80026 |
| Pain Symptom Manage | 0.426561 |
| cancer fatigue | 0.565306 |
| fatigue levels | 0.472762 |
| Healthy fatigue | 0.483034 |
|
| et al. | 0.481346 |
| fatigue scores | 0.45955 |
| study | 0.418279 |
| Oncol Nurs Forum | 0.493357 |
| Brief Fatigue Inventory | 0.449476 |
| persistent fatigue | 0.499021 |
| fatigue trajectory | 0.465086 |
| acute fatigue | 0.483368 |
| morning fatigue | 0.469862 |
| PUBMED Abstract | 0.401763 |
| label chronic fatigue | 0.506385 |
| reduced fatigue | 0.424645 |
| fatigue management focus | 0.514449 |
| Mental fatigue | 0.462612 |
| Abstract | 0.416565 |
| Clin Oncol | 0.445675 |
| breast cancer | 0.789754 |
| fatigue management. | 0.459872 |
| postoperative fatigue | 0.468487 |
| severe fatigue category | 0.447818 |
| Lee Fatigue Scale | 0.483435 |
| chronic fatigue syndrome | 0.508959 |
| cancer | 0.840288 |
| chronic cancer-related fatigue | 0.523182 |
|
CLICK HERE |
| 1571 |
National Cancer Institute |
Html |
en |
Oropharyngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of oropharyngeal cancer. |
| clinical trial | 0.317401 |
| treatment | 0.389236 |
| lymph node | 0.268655 |
| radiation therapy | 0.666089 |
|
| cancer | 0.907557 |
| clinical trials | 0.51831 |
| cancer cells | 0.317956 |
|
CLICK HERE |
| 1654 |
National Cancer Institute |
Html |
en |
Gerson Therapy (PDQ®)–Health Professional Version |
Expert-reviewed information summary about Gerson therapy as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| complex regimen | 0.484073 |
| prescribed conventional regimen | 0.48627 |
| body | 0.480118 |
| treatment regimen | 0.476762 |
| New York City | 0.503592 |
| American Cancer Society | 0.4659 |
| normal metabolic state | 0.454242 |
| Gerson’s data | 0.572285 |
| coffee enemas | 0.55048 |
| Gerson Research Organization | 0.580725 |
| cancer information summary | 0.482421 |
| cancer therapies | 0.454018 |
| colorectal cancer | 0.455812 |
| diet regimen | 0.532413 |
| Gerson therapy | 0.918805 |
| patients | 0.555703 |
| cancer patients | 0.512802 |
| Gerson’s life | 0.570445 |
| Gerson regimen | 0.719238 |
| flaxseed oil | 0.455436 |
| diet group | 0.469079 |
| Charlotte Gerson Straus | 0.587654 |
| injectable crude liver | 0.462964 |
| gonzalez regimen | 0.487953 |
| potassium | 0.46778 |
|
| United States | 0.4578 |
| Gerson approach | 0.560315 |
| cancer cells | 0.467412 |
| 5-year survival rate | 0.480223 |
| cancer cell biology | 0.469353 |
| Gerson regimen. | 0.568736 |
| A. Pancreatic enzymes | 0.456434 |
| potassium solution | 0.46218 |
| excess sodium | 0.454821 |
| Gerson Hospital | 0.567697 |
| Gerson approach. | 0.560098 |
| National Cancer Institute | 0.466567 |
| Desiccated liver capsules | 0.461935 |
| stage I–II patients | 0.465698 |
| New York | 0.508367 |
| Gerson segment | 0.563678 |
| pancreatic enzymes | 0.529579 |
| Gerson Institute | 0.579619 |
| healthy liver function. | 0.462886 |
| Gerson diet | 0.622931 |
| crude liver extract | 0.544679 |
| melanoma patients | 0.45525 |
| cancer | 0.570183 |
| Max Gerson | 0.650691 |
|
CLICK HERE |
| 1697 |
National Cancer Institute |
Html |
en |
High-Dose Vitamin C (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer. |
| cancer treatment | 0.409014 |
| Vitamin C levels | 0.46062 |
| chemotherapy | 0.385658 |
| PDQ cancer information | 0.495143 |
| Cancer Complementary | 0.400016 |
| vitamin C therapy | 0.473688 |
| vitamin C. Patients | 0.500759 |
| vitamin C. Studies | 0.500091 |
| clinical trials | 0.625144 |
| cancer information summary | 0.452988 |
| laboratory studies | 0.446817 |
| alternative cancer therapies | 0.39781 |
| clinical trial | 0.386901 |
| high doses | 0.433559 |
| prostate cancer cells | 0.388026 |
| CAM cancer research | 0.38618 |
| ovarian cancer | 0.395778 |
| malignant mesothelioma | 0.387621 |
| High-Dose Vitamin C. | 0.544572 |
| patients | 0.543391 |
| cancer patients | 0.435773 |
| NCI PDQ cancer | 0.414799 |
| cancer information database | 0.396035 |
| effects | 0.387385 |
|
| Therapies Editorial Board | 0.399092 |
| cancer information | 0.505736 |
| treatment | 0.52957 |
| breast cancer cells | 0.389833 |
| intravenous high-dose vitamin | 0.577226 |
| Complementary Therapies Editorial | 0.414088 |
| Drug Administration | 0.422556 |
| Cancer Information Specialist | 0.391085 |
| dehydroascorbic acid | 0.390795 |
| cancer cells | 0.552348 |
| Cancer Information Service | 0.451182 |
| anticancer drugs | 0.396426 |
| high-dose ascorbic acid | 0.545315 |
| National Cancer Institute | 0.563244 |
| alternative medicine | 0.442263 |
| health care | 0.392613 |
| advanced pancreatic cancer | 0.416341 |
| high-dose IV vitamin | 0.624976 |
| vitamin C treatment | 0.515175 |
| breast cancer | 0.420605 |
| animal studies | 0.461706 |
| alternative therapies | 0.414436 |
| high-dose vitamin | 0.916436 |
| cancer information summaries | 0.396462 |
|
CLICK HERE |
| 1873 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino. |
| Obstet Gynecol | 0.426292 |
| Major FJ | 0.422403 |
| sarcomas uterinos | 0.471793 |
| cisplatin as | 0.411109 |
| Markman M | 0.40448 |
| gynecologic cancer | 0.405911 |
| prognostic factors | 0.405684 |
| Brunetto VL | 0.40512 |
| Sin embargo | 0.405423 |
| or without paclitaxel | 0.411277 |
| fase ii | 0.413551 |
| Ifosfamide treatment | 0.404047 |
| endometrial stromal sarcoma | 0.415162 |
| Radiat Oncol Biol | 0.40725 |
| siguientes puntos | 0.405418 |
| oncology group study | 0.684258 |
| stromal sarcomas previously | 0.409618 |
| patologÃa equivocada | 0.404764 |
| Barrett RJ | 0.404588 |
| Kilgore L | 0.404374 |
| recurrent or metastatic | 0.405758 |
| mixed mesodermal tumors | 0.448955 |
| Gynecologic Oncology Group | 0.969258 |
| Gynecol Oncol | 0.445429 |
| Filiaci V | 0.404525 |
|
| Beecham J | 0.404572 |
| or recurrent leiomyosarcoma | 0.405872 |
| Blessing JA | 0.5678 |
| meses vs | 0.434084 |
| Organización Mundial | 0.408363 |
| pilot study | 0.40409 |
| sarcomas mesodérmicos mixtos | 0.406902 |
| Smith MR | 0.405644 |
| as second-line chemotherapy | 0.406079 |
| or recurrent | 0.412147 |
| New York | 0.404218 |
| Peters WA | 0.405698 |
| Clin Oncol | 0.49692 |
| combination chemotherapy | 0.409211 |
| verdaderos sarcomas | 0.414072 |
| Oncol Biol Phys | 0.407314 |
| cuerpo uterino | 0.408492 |
| elementos homólogos | 0.406306 |
| estadio iii | 0.405213 |
| Rosenshein N | 0.4046 |
| stromal sarcoma | 0.431127 |
| Homesley HD | 0.404643 |
| dimethyl triazenoimidazole carboxamide | 0.404595 |
| with or without | 0.432244 |
|
CLICK HERE |
| 1878 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) masculino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) masculino. |
| Giordano SH | 0.546628 |
| Italian Oncology Group | 0.503266 |
| aromatase inhibitors | 0.504835 |
| Sin embargo | 0.505052 |
| accessed october | 0.502081 |
| American Cancer Society | 0.521913 |
| sumario tratamiento | 0.50893 |
| PALB2 mutations | 0.502161 |
| Terapia sistémica preoperatoria | 0.504717 |
| Instituto Nacional | 0.507139 |
| Vlamis V | 0.505558 |
| male breast | 0.773618 |
| DeVita VT Jr | 0.502939 |
| Wong GY | 0.505822 |
| population-based study | 0.506079 |
| carcinoma lobulillar | 0.502812 |
| hereditary male breast | 0.514858 |
| estadificación tnm | 0.502579 |
| Buzdar AU | 0.511225 |
| breast carcinoma | 0.529746 |
| German Breast Group | 0.523976 |
| Adjuvant therapy with | 0.503518 |
| male breast carcinoma | 0.523697 |
| Cancer Facts | 0.511201 |
| parientes mujeres | 0.50281 |
|
| tumores pten | 0.506695 |
| Cancer Res Treat | 0.581998 |
| National Cancer Institute | 0.509524 |
| or without gonadotropin-releasing | 0.502999 |
| PDQ Tratamiento | 0.571327 |
| versus ia | 0.508803 |
| Hortobagyi GN | 0.519998 |
| Intern Med | 0.505973 |
| cancer susceptibility | 0.510328 |
| cases from | 0.502419 |
| metastatic breast | 0.510618 |
| Clin Oncol | 0.505305 |
| IA vs | 0.504284 |
| Physician Data Query | 0.502682 |
| breast cancer | 0.966614 |
| estadios tnm | 0.502728 |
| Oncology Group Phase | 0.503374 |
| Aromatase inhibitors with | 0.503642 |
| PDQ Sofocos | 0.507587 |
| Current management | 0.505493 |
| Oncology Group | 0.504752 |
| Borgen PI | 0.505535 |
| Hormonal treatment | 0.502423 |
| Breast Cancer Res | 0.608904 |
|
CLICK HERE |
| 2001 |
National Cancer Institute |
Html |
es |
Familiares a cargo de pacientes de cáncer: funciones y desafíos (PDQ®)–Versión para profesionales de salud |
Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas. |
| etapa final | 0.435131 |
| Cancer Communication Assessment | 0.482566 |
| giving bad news | 0.42261 |
| to breast | 0.424042 |
| Sin embargo | 0.471583 |
| receiving palliative care | 0.419812 |
| American Cancer Society | 0.47018 |
| Family support | 0.41866 |
| family to breast | 0.421621 |
| CA Cancer | 0.459636 |
| Given BA | 0.442227 |
| Communication Assessment Tool | 0.434693 |
| Rose JH | 0.438883 |
| family meetings | 0.426208 |
| Estados Unidos | 0.421866 |
| Support Care | 0.447919 |
| Caregivers Based | 0.422755 |
| Palliat Care | 0.44789 |
| patients with | 0.44256 |
| Pain Symptom Manage | 0.455568 |
| Support Oncol | 0.41857 |
| Baile WF | 0.422726 |
| Family Caregiver Support | 0.426151 |
| family caregivers | 0.94013 |
| Crit Care Nurs | 0.421936 |
|
| Oncol Nurs Forum | 0.49008 |
| with family caregivers | 0.435774 |
| Care Cancer | 0.474055 |
| Cancer Facts | 0.43863 |
| Arnold RM | 0.422137 |
| palliative care | 0.565514 |
| Hosp Palliat Care | 0.420581 |
| paciente cumpla | 0.459325 |
| terminally ill patients | 0.428058 |
| Family caregiver quality | 0.42241 |
| communication skills | 0.434733 |
| cancer pain | 0.552042 |
| Crit Care | 0.427432 |
| Palliat Med | 0.438559 |
| Given CW | 0.427811 |
| breast cancer | 0.524972 |
| Arch Intern Med | 0.454734 |
| Conducting family meetings | 0.417671 |
| Baider L | 0.421555 |
| caregivers with | 0.421979 |
| placing family meetings | 0.417694 |
| Crit Care Med | 0.422158 |
| symptoms among caregivers | 0.425057 |
| cancer communication | 0.540368 |
|
CLICK HERE |
| 2038 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de piel (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| nevo atÃpico | 0.426748 |
| almacena agua | 0.428194 |
| voluntarios sanos | 0.420911 |
| filtros solares | 0.422801 |
| ropa protectora | 0.423732 |
| menor exposición | 0.423337 |
| protector solar | 0.980296 |
| protector solar ayuda | 0.457908 |
| siguientes ejemplos | 0.47268 |
| luz solar | 0.660447 |
| vitamina d | 0.429105 |
| National Cancer Institute | 0.427791 |
| piel melanoma | 0.815892 |
| Instituto Nacional | 0.448341 |
|
| lunares benignos | 0.424057 |
| antecedentes familiares | 0.421492 |
| lámparas solares | 0.426025 |
| suficientes estudios | 0.422469 |
| Physician Data Query | 0.500422 |
| radiación uv | 0.839863 |
| Estados Unidos | 0.55931 |
| vitamina b3 | 0.46569 |
| suficiente ejercicio | 0.427407 |
| prevención revisa | 0.424823 |
| PDQ Prevención | 0.445149 |
| siguientes sustancias | 0.424243 |
| radiación ultravioleta | 0.557367 |
| siguientes sumarios | 0.449523 |
|
CLICK HERE |
| 4393 |
National Cancer Institute |
Html |
en |
Care for Childhood Cancer Survivors |
Survivorship care for children who have been treated for cancer is important. Get your child's treatment summary, survivorship plan, and recommendations on follow-up care clinics. Learn about long-term and late effects. |
| cancer treatment | 0.326817 |
| child needs | 0.304086 |
| follow-up care plan | 0.413114 |
| Planning fact sheet | 0.303028 |
| type | 0.300894 |
| health care team | 0.507646 |
| children | 0.315621 |
| follow-up care clinics | 0.3448 |
| survivorship clinics | 0.2728 |
| increased risk | 0.28401 |
| clinical trial | 0.299772 |
| survivorship care | 0.448293 |
| follow-up care visits | 0.396149 |
| child’s recovery | 0.291653 |
| Cancer Survivorship Care | 0.352592 |
| physical late effects | 0.431203 |
| survivorship care plan | 0.433534 |
| late side effects | 0.29008 |
| family health history | 0.303512 |
| health problems | 0.288413 |
| cognitive late effects | 0.426207 |
| Treatment dates | 0.285186 |
| radiation therapy | 0.304846 |
| Supportive care | 0.276073 |
| new routines | 0.26175 |
|
| long-awaited time | 0.26767 |
| late effects | 0.939895 |
| child | 0.816649 |
| treatment summary | 0.334731 |
| treatment information | 0.286208 |
| Emotional late effects | 0.333335 |
| survivor support groups | 0.293019 |
| treatment | 0.559585 |
| new phase | 0.261152 |
| post-traumatic stress disorder | 0.292738 |
| follow-up care plans | 0.34673 |
| children’s cancer | 0.274057 |
| palliative care | 0.276488 |
| Childhood Cancer | 0.261784 |
| Late Effects Directory | 0.342069 |
| child receive | 0.286057 |
| mental health support | 0.300564 |
| Survivorship care plans | 0.341053 |
| Family-based care | 0.275482 |
| child’s ability | 0.286297 |
| long-term side effects | 0.358965 |
| cancer | 0.37733 |
| follow-up care | 0.618265 |
| time | 0.296976 |
|
CLICK HERE |
| 15983 |
National Cancer Institute |
Video |
en |
Human Papillomavirus (HPV) | Did You Know? |
Highlighting key topics in cancer surveillance, this video from the National Cancer Institute (NCI) looks at Human Papillomavirus trends in the United States.
Here is NCI's information on HPV:
http://www.cancer.gov/hpv-factsheet
Find more cancer statistics from NCI's Surveillance, Epidemiology, and End Results (SEER) Program:
http://www.seer.cancer.gov |
| cancer statistics | 0.370109 |
| 01 | 0.310231 |
| HPV Infection | 0.628855 |
| Clark Hansen | 0.355498 |
| Normal Pap | 0.357467 |
| HPV Treatment | 0.637769 |
| Epidemiology | 0.310948 |
| Beautiful Ashes Testimonial | 0.401047 |
| JoAnna Wawrzycki_Rutland Regional | 0.401453 |
| MD | 0.32002 |
| Dr. Jennifer Lang | 0.413448 |
| American Sexual Health | 0.40243 |
| Sherry Livingston | 0.355463 |
| Tricia | 0.323082 |
| Abnormal PAPs | 0.364897 |
| Program | 0.311153 |
| hpv symptoms | 0.677726 |
| Duration | 0.809923 |
| HPV Vaccine | 0.648709 |
| autoplay | 0.333379 |
| key topics | 0.369348 |
| cancer surveillance | 0.370487 |
| NCI | 0.341035 |
| Introduction | 0.310463 |
|
| Warts Treatment | 0.357942 |
| Human Papilloma Virus | 0.411812 |
| Regional Medical Center | 0.493632 |
| United States | 0.36887 |
| Sym Tv | 0.364893 |
| Natural History | 0.359855 |
| Lauren Brim | 0.367672 |
| video | 0.322853 |
| Anderson Cancer Center | 0.410044 |
| DocMikeEvans | 0.310884 |
| National Cancer Institute | 0.4288 |
| views | 0.496544 |
| Cured Her HPV | 0.595526 |
| Cure HPV Naturally | 0.688172 |
| http://www.seer.cancer.gov | 0.311956 |
| Human Papillomavirus trends | 0.438626 |
| HPV Myths | 0.614283 |
| Rutland Regional Medical | 0.400648 |
| CBS News | 0.355791 |
| hpv | 0.931128 |
| common HPV symptoms | 0.674318 |
| dramatichealth | 0.310434 |
| Terri Bork | 0.36584 |
| Natural Treatments | 0.357354 |
|
CLICK HERE |